FDA Approves Elura for Weight Loss in Cats with Chronic Kidney Disease

U.S. Food and Drug Administration sent this bulletin at 10/19/2020 11:36 AM EDT

If your email program has trouble displaying this email, view as a webpage.
US Food and Drug Administration

FDA Approves Elura for Weight Loss in Cats with Chronic Kidney Disease

The U.S. Food and Drug Administration has approved Elura (capromorelin oral solution), the second drug approved for management of weight loss in cats and the first drug approved specifically for the management of weight loss in cats with chronic kidney disease.

Cats with chronic kidney disease (CKD) may begin to lose weight prior to diagnosis and typically continue to lose weight as the disease progresses. This weight loss can worsen cats’ prognosis and shorten their lifespan.

Capromorelin is a ghrelin receptor agonist known to increase appetite and weight gain and is approved as ENTYCE for appetite stimulation in dogs. Elura is the second product that the FDA has approved for the management of unintended weight loss in cats.

Read More Button


You are subscribed to updates from FDA's Center for Veterinary Medicine.